HOMOGENOUS ANTIBODY DRUG CONJUGATES VIA ENZYMATIC METHODS
First Claim
1. A method of making an antibody drug conjugate comprising an antibody specifically conjugated to a conjugate moiety comprising:
- contacting an antibody composition comprising the antibody with the conjugate moiety in the presence of a transglutaminase under a condition sufficient to generate the antibody drug conjugate, wherein at least about 50% of the antibody in the antibody composition is glycosylated in the Fc-region, and wherein the conjugate moiety is conjugated to an endogenous acceptor glutamine residue on the antibody.
3 Assignments
0 Petitions
Accused Products
Abstract
The present application in one aspect provide Fc-containing polypeptide conjugates comprising an Fc-containing polypeptide conjugated to a conjugate moiety, wherein the Fc-containing polypeptide comprises an N-glycosylated Fc region comprising an acceptor glutamine residue flanked by an N-glycosylation site and wherein the conjugate moiety is conjugated to the Fc-containing polypeptide via the acceptor glutamine residue. Also provided are methods of making such Fc-containing polypeptide conjugates by using a wildtype or engineered transglutaminases. Further provided are engineered transglutaminases specifically designed for carrying out such reactions.
-
Citations
20 Claims
-
1. A method of making an antibody drug conjugate comprising an antibody specifically conjugated to a conjugate moiety comprising:
- contacting an antibody composition comprising the antibody with the conjugate moiety in the presence of a transglutaminase under a condition sufficient to generate the antibody drug conjugate, wherein at least about 50% of the antibody in the antibody composition is glycosylated in the Fc-region, and wherein the conjugate moiety is conjugated to an endogenous acceptor glutamine residue on the antibody.
- View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18)
-
19. A method of making an antibody drug conjugate comprising an antibody specifically conjugated to a conjugate moiety comprising a small molecule handle and an active moiety comprising:
-
a) contacting an antibody composition comprising the antibody with the small molecule handle in the presence of a transglutaminase under a condition sufficient to generate an intermediate conjugate comprising the antibody specifically conjugated to the small molecule handle, and b) contacting the intermediate conjugate with the active moiety thereby obtaining the antibody drug conjugate, wherein at least about 50% of the antibody in the antibody composition is glycosylated in the Fc-region, and wherein the conjugate moiety is conjugated to an endogenous acceptor glutamine residue on the antibody. - View Dependent Claims (20)
-
Specification